Publications
July 14, 2021
International Journal of Toxicology
Preclinical Safety Assessment and Toxicokinetics of Apitegromab, an Antibody Targeting Proforms of Myostatin for the Treatment of Muscle-Atrophying Disease
May 11, 2021
Advances in Therapy
A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular Atrophy
March 22, 2021
International Journal of Toxicology
Nonclinical Development of SRK-181: An Anti-Latent TGFβ1 Monoclonal Antibody for the Treatment of Locally Advanced or Metastatic Solid Tumors
Posters
November 2021
36th Society for Immunotherapy of Cancer (SITC) Annual Meeting
First-in-Human Phase 1 Trial of SRK-181: A Latent TGFβ1 inhibitor, Alone or in Combination with Anti-PD-(L)1 Treatment in Patients with Advanced Solid Tumors (DRAGON trial) (#532)
October 2021
2021 World Congress of Neurology (WCN)
Relationship of Pharmacokinetics and Pharmacodynamics to Apitegromab Efficacy in Patients with Later-onset Spinal Muscular Atrophy (Types 2 and 3 SMA): Results from the TOPAZ Study (Poster #EP1150)
September 2021
2021 Child Neurology Society (CNS) Annual Meeting
Efficacy of Apitegromab in Patients with Later-Onset Spinal Muscular Atrophy (SMA Types 2 and 3): Responder Analysis from the Phase 2 TOPAZ Study (#310)